

Novuson[®] Surgical Awarded \$1.5 M Grant by NIH to Advance Direct Therapeutic Ultrasound (DTU)[™] Technology Platform

BOTHELL, WA (March 14, 2016) - Novuson Surgical, a Bothell, WA based medical device company, has been awarded a \$1.5M Phase 2 SBIR grant by the National Institutes of Health (NIH) National Institute of General Medical Sciences to further develop An Active Hemostatic Clamping Device For Bloodless Surgery And Trauma.

Novuson, a spinout from the University of Washington's highly regarded Applied Physics Laboratory's Center for Industrial and Medical Ultrasound, is developing its Direct Therapeutic Ultrasound (DTU) technology platform for **cauterization and hemostatic control** in surgical and trauma procedures. DTU technology enables clinicians to perform surgeries more quickly, treat tumors *in situ*, and to rapidly control bleeding associated with traumatic injuries.

“The integration of High Intensity Focused Ultrasound (HIFU) in to the working surfaces of surgical instruments is a novel innovation that will revolutionize a sizeable portion of the 76 million surgical procedures performed in the US each year. Novuson’s DTU technology will dramatically decrease surgery times and reduce blood loss, without all of the complications and risks of current cauterization technologies,” said Stuart B. Mitchell, PhD, Chief Scientific Officer of Novuson. *“We are deeply honored that our colleagues at the NIH have recognized the significant positive impact this technology will have on patient outcomes.”*

Bleeding complicates surgical procedures and significantly contributes to the majority of the approximately 120,000 trauma deaths per year.

“Direct Therapeutic Ultrasound (DTU) is a valuable technology which will limit bleeding, prevent significant blood loss, and help prevent the "bloody vicious cycle" of Acidosis, Hypothermia and Coagulopathy in trauma,” said Juan A. Asensio, MD, FACS, FCCM, FRCS (England), KM. *“Early control of bleeding will also limit blood product transfusion with its inherent immunological consequences, leading to improved patient outcomes. This will enable clinicians to significantly reduce healthcare costs and save lives.”*

About Novuson Surgical: Novuson Surgical is a privately held company based in Bothell, WA. Novuson Surgical's patented technology delivers Direct Therapeutic Ultrasound (DTU) energy for cauterization and hemostatic control without transmission of electricity through the patient, and provides safety and predictability in the most critical surgical applications. For more information, please visit www.novuson.com.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. For more information about NIH and its programs, visit www.nih.gov.

Contact:

Jim Bazzinotti
Novuson Surgical, Inc.
T: +1.425.481.7165
Jbazzinotti@novuson.com